Generic Name and Formulations:
Sodium hyaluronate 20mg/2mL; soln for intra-articular inj.
Indications for HYALGAN:
Osteoarthritis of the knee in patients who have failed nonpharmacologic therapy and analgesics (eg, acetaminophen).
Prior to treatment: remove joint effusion (use separate syringe), if present; and give local anesthetic (eg, lidocaine) by SC inj. Inject 2mL intra-articularly in each affected knee weekly for 5 weeks. Use separate syringes for each knee.
Infection or skin disease at inj site.
Treatment cycle <3 injections: not recommended. Avian protein, feather, egg allergy. Avoid strenuous activity within 48hrs after injection. Pregnancy. Nursing mothers.
Avoid disinfectants with quaternary ammonium salts. Concomitant other intra-articular injectables: not recommended.
Inj site pain, local reactions, transient knee inflammation.
Single-use vials—1; Single-use prefilled syringes—1
Renal and Urology News Articles
- Robotic Partial Nephrectomy Mostly Superior to Other Surgeries
- FDA Requires Safety Label Changes for Fluoroquinolones
- AV Access at Hemodialysis Initiation Less Likely Among Women
- Development of Clinically Evident Gout: A Closer Look at Elevated Serum Urate Levels
- Apixaban Is Safest Direct Oral Anticoagulant vs Warfarin
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)